Von Willebrand Disease Type 2A: An Update.

Area of Science:

• Hematology
• Molecular Biology
• Genetics

Background:

• Von Willebrand disease (VWD) is the most common inherited bleeding disorder, caused by dysfunctional or deficient von Willebrand factor (VWF).
• Type 2A VWD represents a qualitative defect characterized by impaired VWF-dependent platelet adhesion, linked to a lack of high- and intermediate-molecular-weight VWF multimers.

Purpose of the Study:

• To provide a comprehensive review of type 2A VWD, encompassing its epidemiology, pathophysiology, clinical presentation, diagnostic methods, molecular basis, and therapeutic strategies.
• To update current understanding of how VWF structural defects impact multimer assembly, proteolytic cleavage, and ligand interactions.

Main Methods:

• Review of existing literature on type 2A VWD.
• Analysis of diagnostic approaches including functional assays, VWF multimer analysis, and genetic testing.
• Examination of molecular and structural studies elucidating VWF variant functions.

Main Results:

• Type 2A VWD is associated with reduced VWF activity/antigen and collagen binding/antigen ratios.
• The underlying defect stems from impaired VWF multimer assembly or increased VWF cleavage by ADAMTS13.
• Clinical manifestations include significant mucocutaneous bleeding, with diagnosis supported by genetic identification of subtype-specific mutations.

Conclusions:

• Type 2A VWD requires a multi-faceted diagnostic approach combining functional, structural, and genetic analyses.
• Understanding the molecular basis of VWF defects is crucial for developing targeted therapies.
• Management strategies are tailored to bleeding severity, involving desmopressin and VWF replacement therapy.